Dorsey & Whitney Trust CO LLC Has $205,000 Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Dorsey & Whitney Trust CO LLC cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 12.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,870 shares of the company’s stock after selling 2,327 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Takeda Pharmaceutical were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Capital Research Global Investors increased its stake in shares of Takeda Pharmaceutical by 3.6% in the fourth quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock worth $204,030,000 after acquiring an additional 503,446 shares during the last quarter. Mondrian Investment Partners LTD increased its stake in shares of Takeda Pharmaceutical by 47.9% in the first quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after acquiring an additional 3,912,569 shares during the last quarter. Brandes Investment Partners LP increased its stake in shares of Takeda Pharmaceutical by 47.1% in the fourth quarter. Brandes Investment Partners LP now owns 2,651,265 shares of the company’s stock worth $37,834,000 after acquiring an additional 849,229 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after acquiring an additional 356,069 shares during the last quarter. Finally, OLD Mission Capital LLC increased its stake in shares of Takeda Pharmaceutical by 1,440.9% in the fourth quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after acquiring an additional 973,935 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $14.82 on Friday. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $16.39. The stock’s 50-day moving average is $14.14 and its two-hundred day moving average is $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The firm has a market cap of $47.16 billion, a P/E ratio of 26.95, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The company had revenue of $7.75 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. On average, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.